TMLB-G9

TMLB-G9 is an orally active B3GAT3 inhibitor (human Kd = 0.72 μM). TMLB-G9 blocks glycosaminoglycan biosynthesis and inhibits chondroitin sulfate biosynthesis in hepatocellular carcinoma cells. TMLB-G9 induces apoptosis by upregulating cleaved PARP and cleaved caspase-3. TMLB-G9 induces G0/G1 cell cycle arrest by upregulating Rb and downregulating CDK1, CDK2, Cyclin A2, Cyclin E1, and phosphorylated Rb. TMLB-G9 inhibits migration and invasion by reversing epithelial-mesenchymal transition, manifested as upregulation of E-cadherin and downregulation of N-cadherin, vimentin, MMP-2, MMP-9, and ZEB1. TMLB-G9 inhibits colony formation. TMLB-G9 exhibits broad-spectrum antitumor activity against multiple cancer cell lines. TMLB-G9 can be used for research on hepatocellular carcinoma.

Para uso exclusivo en investigación. No vendemos a pacientes.

  • No. CAS: 3127781-85-2
  • Fòrmula: C33H26N4O7
  • Peso molecular:590.58
  • Almacenamiento:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Actividad biológica
  • Chemical Information
  • Protocolo
  • Pureza y Documentación
  • Referencias
  • Help & FAQs
MOQ
Minimum order quantity
100 mg

Obtener un presupuesto En stock

Other size
Obtener un presupuesto
Please select quantity
Amount: USD 0.00